|
|
Article: Pro-Pharmaceuticals & Mount Sinai School of Medicine Announce New Liver Fibrosis Research Collaboration.
- Article from:
- Business Wire
- Article date:
- May 24, 2006
CopyrightCOPYRIGHT 2006 Business Wire. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
NEWTON, Mass. -- Pro-Pharmaceuticals, Inc. (Amex: PRW), a developer of novel nanotechnology carbohydrate therapeutics, today announced it has entered into a research collaboration with Mount Sinai School of Medicine to evaluate the anti-fibrotic effects of some of the Company's novel, carbohydrate compounds. Mount Sinai has one of the world's largest, most productive and well-respected liver programs. Pro-Pharmaceuticals is engaged in the discovery, development and commercialization of carbohydrate-based therapeutic compounds for advanced treatment of cancer, liver, microbial, cardiovascular and inflammatory diseases, and viral infections.
According to the ...
Related newspaper, magazine, and journal articles:
|
|
Article: Data from Mount Sinai School of Medicine provide ...
Health & Medicine Week;
March 3, 2008 ;
700+ words
... ... L Friedman and colleagues, Mount Sinai School of Medicine. The researchers ... the diagnosis and treatment of liver disease." Friedman and colleagues published ... information, contact S.L. Friedman, Mount Sinai School of Medicine, Division ...
|
|